Nitromemantine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414437

CAS#: 765890-91-3

Description: Nitromemantine is a derivative of memantine developed in 2006 for the treatment of Alzheimer's disease. It has been shown to reduce excitotoxicity mediated by over-activation of the glutamatergic system, by blocking NMDA receptors.

Chemical Structure

img
Nitromemantine
CAS# 765890-91-3
Instruction

Theoretical Analysis

MedKoo Cat#: 414437
Name: Nitromemantine
CAS#: 765890-91-3
Chemical Formula: C14H24N2O3
Exact Mass: 268.18
Molecular Weight: 268.360
Elemental Analysis: C, 62.66; H, 9.01; N, 10.44; O, 17.89

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Nitromemantine; NMI6979; NMI-6979; NMI 6979; YQW36; YQW 36; YQW-36

IUPAC/Chemical Name: Tricyclo(3.3.1.13,7)decan-1-ol, 3-amino-5,7-diethyl-, 1-nitrate

InChi Key: SENUTBBWBZZNRT-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H24N2O3/c1-3-11-5-12(4-2)7-13(15,6-11)10-14(8-11,9-12)19-16(17)18/h3-10,15H2,1-2H3

SMILES Code: CCC1(C2)CC3(CC)CC2(N)CC(C3)(O[N+]([O-])=O)C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 268.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease. Mol Neurodegener. 2014 Nov 14;9:48. doi: 10.1186/1750-1326-9-48. PMID: 25394486; PMCID: PMC4237769.

2: Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Piña-Crespo JC, Lipton SA. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2518-27. doi: 10.1073/pnas.1306832110. Epub 2013 Jun 17. Erratum in: Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13691. Erratum in: Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3630. Erratum in: Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):E3751-2. PMID: 23776240; PMCID: PMC3704025.

3: Takahashi H, Xia P, Cui J, Talantova M, Bodhinathan K, Li W, Saleem S, Holland EA, Tong G, Piña-Crespo J, Zhang D, Nakanishi N, Larrick JW, McKercher SR, Nakamura T, Wang Y, Lipton SA. Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease. Sci Rep. 2015 Oct 19;5:14781. doi: 10.1038/srep14781. Erratum in: Sci Rep. 2016;6:20750. Saleem, Sofiyan [added]. PMID: 26477507; PMCID: PMC4609936.

4: Takahashi H, Xia P, Cui J, Talantova M, Bodhinathan K, Li W, Saleem S, Holland EA, Tong G, Piña-Crespo J, Zhang D, Nakanishi N, Larrick JW, McKercher SR, Nakamura T, Wang Y, Lipton SA. Corrigendum: Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease. Sci Rep. 2016 Feb 12;6:20750. doi: 10.1038/srep20750. Erratum for: Sci Rep. 2015;5:14781. Saleem, Sofiyan [added]. PMID: 26867695; PMCID: PMC4751459.

5: Nakamura T, Lipton SA. Cell death: protein misfolding and neurodegenerative diseases. Apoptosis. 2009 Apr;14(4):455-68. doi: 10.1007/s10495-008-0301-y. PMID: 19130231.

6: Dal Prà I, Chiarini A, Armato U. Antagonizing amyloid-β/calcium-sensing receptor signaling in human astrocytes and neurons: a key to halt Alzheimer's disease progression? Neural Regen Res. 2015 Feb;10(2):213-8. doi: 10.4103/1673-5374.152373. PMID: 25883618; PMCID: PMC4392667.

7: Nakamura T, Lipton SA. Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies. Cell Calcium. 2010 Feb;47(2):190-7. doi: 10.1016/j.ceca.2009.12.009. Epub 2010 Jan 8. PMID: 20060165; PMCID: PMC2875138.

8: Rush T, Buisson A. Reciprocal disruption of neuronal signaling and Aβ production mediated by extrasynaptic NMDA receptors: a downward spiral. Cell Tissue Res. 2014 May;356(2):279-86. doi: 10.1007/s00441-013-1789-1. Epub 2014 Feb 5. PMID: 24496511.

9: Nakanishi N, Kang YJ, Tu S, McKercher SR, Masliah E, Lipton SA. Differential Effects of Pharmacologic and Genetic Modulation of NMDA Receptor Activity on HIV/gp120-Induced Neuronal Damage in an In Vivo Mouse Model. J Mol Neurosci. 2016 Jan;58(1):59-65. doi: 10.1007/s12031-015-0651-1. Epub 2015 Sep 15. PMID: 26374431; PMCID: PMC4821006.

10: Nakamura T, Lipton SA. Protein S-Nitrosylation as a Therapeutic Target for Neurodegenerative Diseases. Trends Pharmacol Sci. 2016 Jan;37(1):73-84. doi: 10.1016/j.tips.2015.10.002. Epub 2015 Dec 17. PMID: 26707925; PMCID: PMC4698225.